Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Patent protection for CRISPR: an ELSI review.

Sherkow JS.

J Law Biosci. 2017 Dec 7;4(3):565-576. doi: 10.1093/jlb/lsx036. eCollection 2017 Dec. No abstract available.

2.

Fortune and hindsight: gene patents' muted effect on medical practice.

Sherkow JS, Abbott R.

Br Med Bull. 2018 Jun 1;126(1):37-45. doi: 10.1093/bmb/ldy009.

PMID:
29608656
3.

CRISPR, Patents, and the Public Health.

Sherkow JS.

Yale J Biol Med. 2017 Dec 19;90(4):667-672. eCollection 2017 Dec.

4.

Patent protection for microbial technologies.

Sherkow JS.

FEMS Microbiol Lett. 2017 Nov 1;364(20). doi: 10.1093/femsle/fnx205. Review.

PMID:
29029027
5.

Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic.

Nicol D, Eckstein L, Morrison M, Sherkow JS, Otlowski M, Whitton T, Bubela T, Burdon KP, Chalmers D, Chan S, Charlesworth J, Critchley C, Crossley M, de Lacey S, Dickinson JL, Hewitt AW, Kamens J, Kato K, Kleiderman E, Kodama S, Liddicoat J, Mackey DA, Newson AJ, Nielsen J, Wagner JK, McWhirter RE.

Genome Med. 2017 Sep 25;9(1):85. doi: 10.1186/s13073-017-0475-4.

6.
7.

Patent pools for CRISPR technology-Response.

Contreras JL, Sherkow JS.

Science. 2017 Mar 24;355(6331):1274-1275. doi: 10.1126/science.aan0818. No abstract available.

PMID:
28336632
8.

CRISPR, surrogate licensing, and scientific discovery.

Contreras JL, Sherkow JS.

Science. 2017 Feb 17;355(6326):698-700. doi: 10.1126/science.aal4222. No abstract available.

PMID:
28209863
9.

Patent Law's Reproducibility Paradox.

Sherkow JS.

Duke Law J. 2017 Jan;66(4):845-911.

PMID:
28117563
10.

The rise of the ethical license.

Guerrini CJ, Curnutte MA, Sherkow JS, Scott CT.

Nat Biotechnol. 2017 Jan 10;35(1):22-24. doi: 10.1038/nbt.3756. No abstract available.

PMID:
28072792
11.

Protecting products versus platforms.

Sherkow JS.

Nat Biotechnol. 2016 May 6;34(5):462-5. doi: 10.1038/nbt.3553. No abstract available.

PMID:
27153268
12.

CRISPR: Pursuit of profit poisons collaboration.

Sherkow JS.

Nature. 2016 Apr 14;532(7598):172-3. doi: 10.1038/532172a. No abstract available.

PMID:
27075081
13.

The changing life science patent landscape.

Rai AK, Sherkow JS.

Nat Biotechnol. 2016 Mar;34(3):292-4. doi: 10.1038/nbt.3504. No abstract available.

PMID:
26963552
14.

The History of Patenting Genetic Material.

Sherkow JS, Greely HT.

Annu Rev Genet. 2015;49:161-82. doi: 10.1146/annurev-genet-112414-054731. Epub 2015 Oct 6. Review.

PMID:
26442843
15.

Stem cell patents after the america invents act.

Sherkow JS, Scott CT.

Cell Stem Cell. 2015 May 7;16(5):461-4. doi: 10.1016/j.stem.2015.04.015.

16.

Law, history and lessons in the CRISPR patent conflict.

Sherkow JS.

Nat Biotechnol. 2015 Mar;33(3):256-7. doi: 10.1038/nbt.3160. No abstract available.

PMID:
25748913
17.

Myriad stands alone.

Sherkow JS, Scott C.

Nat Biotechnol. 2014 Jul;32(7):620. doi: 10.1038/nbt.2944. No abstract available.

PMID:
25004225
18.

23andMe, the Food and Drug Administration, and the future of genetic testing.

Zettler PJ, Sherkow JS, Greely HT.

JAMA Intern Med. 2014 Apr;174(4):493-4. doi: 10.1001/jamainternmed.2013.14706. No abstract available.

PMID:
24535082
19.

The future of gene patents and the implications for medicine.

Sherkow JS, Greely HT.

JAMA Intern Med. 2013 Sep 23;173(17):1569-70. doi: 10.1001/jamainternmed.2013.10153. No abstract available.

PMID:
23896757
20.

Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements.

Sherkow JS.

Nat Biotechnol. 2013 Apr;31(4):316-7. doi: 10.1038/nbt.2542. No abstract available.

PMID:
23563426
21.

Genomics. What if extinction is not forever?

Sherkow JS, Greely HT.

Science. 2013 Apr 5;340(6128):32-3. doi: 10.1126/science.1236965. No abstract available.

PMID:
23559235

Supplemental Content

Loading ...
Support Center